TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center in El Paso, take a look at the leading medical stories of the week.
Today’s subjects consist of hereditary screening of couples preparing pregnancy, usage of 2 medications in individuals who’ve had a cardiovascular disease, genome-wide association designs and run the risk of for heart disease, and 2 medications to minimize lipoprotein(a).
Program notes:
0:40 Reducing lipoprotein(a)
1:40 Oral medication avoids 2 parts from binding
2:40 What percentage have this concern?
2:54 Polygenic threat ratings and heart problem danger
3:54 Ended up with 46 ratings
4:54 40-50% of dangers included with genes
5:56 Two medications after cardiovascular disease
6:56 No advantage in all comers with cardiac arrest
7:50 Nationwide hereditary provider screening
8:50 9107 couples finished
9:50 Wide variety of illness evaluated
10:50 Genetic therapist for those with increased danger
12:18 End
Records:
Elizabeth: Are polygenic threat ratings of any energy at all in forecasting heart disease?
Rick: Two brand-new research studies of individuals that have actually had a severe cardiovascular disease.
Elizabeth: Nationwide hereditary screening of folks preparing to develop.
Rick: And 2 various methods that minimize lipoprotein(a) levels.
Elizabeth: That’s what we’re speaking about today on TTHealthWatch, your weekly take a look at the medical headings from Texas Tech University Health Sciences Center in El Paso. I’m Elizabeth Tracey, a Baltimore-based medical reporter.
Rick: And I’m Rick Lange, president of Texas Tech University Health Sciences Center in El Paso, where I’m likewise dean of the Paul L. Foster School of Medicine.
Elizabeth: Let’s note it is the American Heart Association (AHA) conference and for that reason 3 out of the 4 research studies we’re speaking about today are from that conference. And I’m going to toss the ball right to you. Let’s speak about decreasing lipoprotein (a), something that you foreshadowed recently.
Rick: Last week, we reported on how essential it was to examine it at a long time. Not just does LDL cholesterol anticipate who is going to have coronary heart illness, however lipoprotein(a) levels do. We’ve got statins to lower LDL levels, however we actually have not established anything till just recently that can reduce lipoprotein(a) levels. I’m going to report on 2 research studies that were reported in JAMA today.
Among them is an oral medication and the other is an injectable. Lipoprotein(a) is made up of an apolipoprotein B-containing, LDL-like particle– wow– that is bound to an apolipoprotein A particle. Now, those 2 things need to integrate together to make lipoprotein(a). The oral medication avoids those 2 things from integrating.
The injectable medication is a little interfering RNA that targets the gene.